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Background: According to current guidelines, endocrine therapy (ET) is recommended as ﬁrst-line
treatment of luminal-like metastatic breast cancer (MBC), whereas chemotherapy (CT) should be
considered in presence of life-threatening disease. In daily practice, CT is often used outside of this
clinical circumstance. Factors inﬂuencing ﬁrst-line choice and the relative impact on outcome are
unknown.
Methods: A consecutive series of luminal-like HER2-negative MBC patients treated from 2004 to 2014
was analyzed to test the association of disease- and patient-related factors with the choice of ﬁrst-line
treatment (ET vs. CT). A propensity score method was used to estimate impact of ﬁrst-line strategy on
outcome.
Results: Of 604 consecutive luminal-like MBC patients identiﬁed, 158 cases were excluded due to un-
known or positive HER2-status. Among 446 HER2-negative cases, 171 (38%) received ﬁrst-line CT. On
multivariate analysis, the only factors signiﬁcantly associated with lower CT use were old age (OR 0.25,
95%C.I. 0.13e0.49) or presence of bone metastases only (OR 0.26, 95%C.I. 0.13e0.53). In propensity score
matched population, no differences were observed between CT and ET as ﬁrst-line treatment either in
terms of overall survival (37.5 months and 33.4 months respectively, log-rank test, P ¼ 0.62) or
progression-free survival (13.3 months and 9.9 months respectively, log-rank test, P ¼ 0.92).
Conclusions: High percentage of patients with luminal-like MBC received CT as ﬁrst-line therapy in real-
life. The choice was mainly driven by age and site of metastases. With the limitations of a non-
randomized comparison, no differences on patients' outcome were observed depending on the ﬁrst-
line strategy.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Breast cancer (BC) is themost common type of cancer inwomen,
with 40,450 estimated deaths in the United States, in 2016 [1].nd Biological Sciences, Uni-
ospital of Udine. Udine, Italy.
otto).
Ltd. This is an open access article uMetastatic disease occurs in approximately 20e50% of patients
with early BC history and in 6e10% of newly diagnosed BC cases [2].
Overall survival (OS) of women with metastatic breast cancer
(MBC) ranges from a few months to many years accordingly with
the BC subtype [3,4], while almost none are deﬁnitely cured.
The optimal sequence of systemic agents for MBC remains un-
known. Considerations about tumor burden, symptoms, expected
toxicities, quality of life, and patient's preferences drive clinicians'
decision-making process. Hormone receptor status and HER2nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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beneﬁt from speciﬁc treatments, but there is no evidence about the
utility ofmaking therapeutic choices on the basis of tumor subtypes
(i.e., luminal A or luminal B or triple negative) [5,6]. Recommen-
dation for endocrine therapy (ET) versus chemotherapy (CT) as
ﬁrst-line treatment of hormone receptor-positive MBC is reported
by the main international guidelines [6,7]. The use of ET is sup-
ported by data showing a therapeutic beneﬁt with less toxicity and
better quality of life in comparison to CT [6e9]. Nevertheless, it is
generally thought that CT is associated with greater and earlier
tumor response, especially in case of high burden of disease. For
patients with hormone receptor-positive and HER2-positive dis-
ease chemotherapy plus HER2-targeted therapy was strongly rec-
ommended, except for highly selected cases for whom clinicians
may offer endocrine therapy [10]. On the contrary, for womenwith
hormone receptor-positive HER2-negative disease the question of
whether to use CT or ET as ﬁrst-line treatment MBC remains, to
date, partially unresolved.
Aim of this study was to describe the use of CT and ET regimens
as ﬁrst-line treatment of women with hormone receptor-positive
HER2-negative MBC, outside the setting of clinical trials, in real
world scenario.
In particular, two main issues were taken into consideration: (i)
to test the association between patient- or disease-related factors
and ﬁrst-line treatment choice (ET vs. CT); and (ii) to explore the
inﬂuence of ﬁrst-line treatment choice (ET vs. CT) in terms of
outcome.
2. Methods
2.1. Study design
This retrospective study analyzed a series of 604 consecutive
patients with luminal-like (i.e. hormone receptor-positive) HER2-
negative MBC treated at the University Hospitals of Naples and
Udine, Italy, between 2004 and 2014. The study population
included women with advanced BC, either newly diagnosed or
recurrent. Patients with HER2-positive (or HER2-unknown) dis-
ease, with second primary tumors and those who did not receive
any active treatment for metastatic disease were excluded. De-
mographic and clinico-pathological data were extracted from
electronic medical records and treated according to strict privacy
standards.
We collected data about CT and ET focusing on ﬁrst-line choice.
Among patients treated with ﬁrst-line CT, the subsequent admin-
istration of maintenance ET in patients without disease progression
at the completion of CT (CT/ET) was also recorded.
According to current guidelines [11], the cutoff point of 1% was
used to deﬁne estrogen receptor (ER) and/or progesterone receptor
(PR) positivity. The cutoff value for the immunohistochemically
determined Ki-67 index to distinguish luminal B was 14% [12]. The
following BC subtypes were deﬁned: “luminal A” (HER2-negative,
Ki-67  14%), “luminal B” (HER2-negative, Ki-67 > 14%).
OS was deﬁned as the time between ﬁrst-line treatment initi-
ation and death from any cause. Progression Free Survival (PFS) was
deﬁned as the time between treatment initiation and tumor pro-
gression or death from any cause. The date of progression was
identiﬁed as the date at which progression was ﬁrst evident (e.g.
imaging, biochemical examination, clinical visit).
The following variables were studied as patient- or disease-
related variables potentially associated with ﬁrst-line choice and/
or as prognostic factors: age (70 vs. <70 years old), body mass
index (BMI>25 vs. 25), performance status (PS) according to the
Eastern Cooperative Oncology Group (ECOG) scale (PS ECOG2 vs.
<2), BC subtypes (luminal B vs. luminal A), onset of MBC (de novoadvanced vs. recurrent disease), number of metastatic sites (2 vs.
1), previous neo-/adjuvant ET and/or CT (yes vs. no), visceral
involvement (yes vs. no), bone only disease (yes vs. no), lung (yes
vs. no), liver (yes vs. no), and central nervous system (CNS, yes vs.
no) metastases.
2.2. Statistical analysis
Patients' demographic and clinico-pathological characteristics
were summarized through descriptive analysis. Continuous vari-
ables were reported through median and interquartile range,
whereas categorical variables were described through frequency
distribution. Factors inﬂuencing the prescription of a ﬁrst-line ET
vs. CT were investigated through uni- and multivariate logistic
regression with odds ratio (OR) calculation. Prognostic factors in
terms of OS and PFS among different treatment subgroups were
tested by Cox regressionwith 95% conﬁdence interval (95%C.I.) both
in uni- and multivariate models. To assess the different impact on
outcome measures of ﬁrst-line treatment choice, population was
sampled and balanced using propensity score matching (PSM),
computed taking in consideration age and performance status at
ﬁrst-line, breast cancer subtypes, onset of advanced disease, pres-
ence of visceral metastases, lung and liver metastases and number
of visceral sites involved. The matching approach was 1:1 nearest
neighbor with caliber of 20%. Differences in survival were tested by
log-rank test and represented by Kaplan-Meier estimator plot. A
landmark analysis with 6 months threshold was performed in or-
der to minimize the bias in the exploratory analysis of the impact of
ET maintenance after CT on outcome: patients who progressed
before 6months had a very low chance of receiving ETmaintenance
and their inclusion in the comparison would have obviously biased
the comparison in favor of the group of patients receiving
maintenance.
3. Results
Of 604 consecutive luminal-like MBC patients identiﬁed, 158
cases were excluded due to unknown or positive HER2-status.
Among 446 HER2-negative cases, ﬁrst-line CT was chosen in 38%
(171/446) of patients. Median age of women treated with ﬁrst-line
ET and CT was 68 (range 39e92) and 58 (range 30e81) years,
respectively. Baseline characteristics of patients according to ﬁrst-
line treatment are summarized in Table 1A.
3.1. Association between patient- or disease-related factors and
ﬁrst-line treatment choice
The individual characteristics of CT and ET groups are showed in
Table 1A. Patients with potentiallymore unfavorable characteristics
such as younger age, good performance status, higher number of
metastatic sites and a greater visceral involvement basically
received CT more often than ET. No differences were observed ac-
cording to the center (Udine vs. Napoli). On multivariate analysis,
age70 years (OR 0.25, 95%C.I. 0.13e0.49, P < 0.0001), or bone only
disease (OR 0.26, 95%C.I. 0.13e0.53, P < 0.0001) were associated
with lower use of CT as ﬁrst treatment. A trend was observed for
performance status (OR 0.48, 95%C.I. 0.23e1.00, P 0.05). Uni- and
multivariate results are showed in Table 2. Of note, in the subgroup
of patients with a recurrent MBC excluding de novo diagnosis, re-
lapsing within 5 years from breast cancer surgery was not signiﬁ-
cantly associated with ﬁrst-line regimen (data not shown).
In a subset of patients, maintenance therapy with ET was given
after initial CT regimen in absence of progressive disease (CT/ET
group). Namely, 88 patients received CT whereas 83 received
CT/ET. Baseline characteristics of patients according to CT strategy
Table 1
Baseline characteristics of the endocrine therapy and chemotherapy groups. Bold values indicate statistically signiﬁcant results.
A- whole study population B- population selected by propensity score matchinga
Characteristic Endocrine therapy N ¼ 275 Chemotherapy N ¼ 171 Endocrine therapy N ¼ 99 Chemotherapy N ¼ 99
N (%) N (%) P value N (%) N (%) P value
Institution
Udine 211 (77%) 127 (74%) 0.56 72 (73%) 72 (73%) 1.00
Napoli 64 (23%) 44 (26%) 27 (27%) 27 (27%)
Age (3 missing)
<70 156 (57%) 145 (86%) <0.0001 76 (77%) 78 (79%) 0.73
70 118 (43%) 24 (14%) 23 (23%) 21 (21%)
Performance status
0/1 217 (79%) 150 (88%) 0.02 82 (83%) 84 (85%) 0.70
2 58 (21%) 21 (12%) 17 (17%) 15 (15%)
Subtype (54 missing)
Luminal A 77 (32%) 32 (22%) 0.03 23 (23%) 23 (23%) 1.00
Luminal B 167 (68%) 116 (78%) 76 (77%) 76 (77%)
De novo advanced disease
93 (34%) 55 (32%) 0.72 33 (33%) 29 (29%) 0.54
Bone only
136 (49%) 35 (20%) <0.0001 32 (32%) 21 (21%) 0.08
Visceral metastases
84 (30%) 99 (58%) <0.0001 47 (47%) 50 (50%) 0.67
Liver metastases
38 (14%) 53 (31%) <0.0001 21 (21%) 24 (24%) 0.64
Lung metastases
34 (12%) 43 (25%) 0.001 23 (23%) 22 (22%) 0.84
CNS metastases
3 (1%) 4 (2%) 0.31 0 (0%) 1 (1%) 0.32
Number of sites
1 218 (79%) 101 (59%) <0.0001 67 (68%) 65 (65%) 0.76
>1 57 (21%) 70 (41%) 32 (32%) 34 (34%)
a Matched by age, performance status, tumor subtype (Luminal A, Luminal B), onset of advanced disease, presence of visceral metastases, presence of liver metastases,
presence of lung metastases, number of metastatic sites.
Table 2
Chemotherapy use by tumor and patient characteristics (vs. endocrine therapy). (BMI, Body Mass Index; CI, Conﬁdence Interval; CNS, Central Nervous System; CT, Chemo-
therapy; ECOG, Eastern Cooperative Oncology Group; ET, Endocrine Therapy; OR, Odds Ratio; NA, not applicable due to multicollinearity). Bold values indicate statistically
signiﬁcant results.
Chemotherapy
Univariate Multivariate
OR [CI 95%] P value OR [CI 95%] P value
Subtype-Luminal B 1.67 [1.04e2.69] 0.03 1.61 [0.85e3.05] 0.14
BMI >25 0.57 [0.37e0.89] 0.01 0.62 [0.37e1.07] 0.09
ECOG performance status >1 0.52 [0.30e0.90] 0.02 0.48 [0.23e1.00] 0.05
Age 70 0.22 [0.13e0.36] <0.0001 0.25 [0.13e0.49] <0.0001
CT naïve 0.60 [0.41e0.88] 0.008 0.93 [0.54e1.60] 0.80
ET naïve 1.35 [0.97e1.88] 0.07 e e
De novo advanced disease 0.93 [0.62e1.39] 0.74 - -
Bone only 0.26 [0.17e0.41] <0.0001 0.26 [0.13e0.53] <0.0001
Liver metastases 2.79 [1.74e4.47] <0.0001 1.49 [0.75e2.98] 0.26
Lung metastases 2.37 [1.44e3.90] 0.001 1.35 [0.64e2.84] 0.43
CNS metastases 2.16 [0.48e9.79] 0.32 e e
Visceral metastases 3.13 [2.10e4.65] <0.0001 NA NA
Number of sites>1 2.65 [1.74e4.04] <0.0001 1.30 [0.63e2.68] 0.47
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data). Disease subtype, metastatic sites, onset of advanced disease,
BMI, age and ECOG performance status were not associated with ET
maintenance. On multivariate analysis, patients not having
received previous (neo- or adjuvant) ET were more likely to receive
an ET maintenance treatment (OR 3.69, 95%C.I. 1.94e7.02;
P < 0.0001). Uni- and multivariate results were showed in
Supplementary Table S2 (Supplementary data). Beyond ﬁrst-line,
clinicians choose to introduce chemotherapy or continue with
endocrine regimens in the same proportion. Somewomen received
ET after one or more chemotherapy lines. Description of thera-
peutic strategy along subsequent lines is presented in Fig. 1.3.2. Outcome according to ﬁrst-line treatment choice (ET vs. CT)
Median follow-up was 52 months. In the whole population
median OS was 36 months, while median PFS was 10.5 months. In
patients treatedwith CTas ﬁrst-line treatment, median OSwas 36.6
months and median PFS was 11.6 months. Among cases treated
with ET as ﬁrst-line treatment, median OS was 35 months and
median PFS was 9.6 months. Comparisons of PFS and OS between
different treatment groups are presented in Fig. 2A.
Clinico-pathological factors were evaluated to test the associa-
tion with outcome measures according to ﬁrst-line therapy
(Table 3). In multivariate analysis, OS was shorter for patients with
Fig. 1. Description of therapeutic strategy (CT, chemotherapy; ET, endocrine therapy).
The following subgroups were deﬁned: choice of CT or ET for patients that have never
received a CT line for MBC [“CT (for the ﬁrst time)” and “ET (CT naive)” respectively],
choice of CT or ET for patients that have already received a CT line for MBC [“CT (no CT
naive)” and “ET (no CT naive)” respectively].
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was associated with number of therapeutic lines for MBC (HR 0.84,
95%C.I. 0.77e0.92) in patients treated with CT. In patients treated
with ET, shorter OSwas associatedwith luminal B subtype (HR 1.86,
95%C.I. 1.27e2.72), poor performance status (HR 1.96, 95%C.I.
1.31e2.95), age 70 (HR 1.83, 95%C.I. 1.31e2.58), and multiple
metastatic sites (HR 1.91, 95%C.I. 1.23e2.97).
In multivariate analysis, shorter PFS was associated with mul-
tiple metastatic sites (HR 1.52, 95%C.I. 1.08e2.12) in patients treated
with CT. In patients treatedwith ET, shorter PFSwas associatedwith
luminal B subtype (HR 1.82, 95%C.I. 1.32e2.50); longer PFS was
associated with being ET naïve (HR 0.65, 95%C.I. 0.49e0.86).
PSM selected a subgroup of 198 patients (99 treated with ET and
99 treated with CT). Baseline characteristics of matched patients by
systemic treatment are summarized in Table 1B. The analysis of the
matched subset showed similar outcome in patients treated with
CT vs. ET, either in terms of OS (37.5 months and 33.4 months
respectively, log-rank test, P ¼ 0.62) or PFS (13.3 months and 9.9
months respectively, log-rank test, P ¼ 0.92). Comparisons of PFS
and OS between matched groups are presented in Fig. 2B.
To explore the impact of ET maintenance on outcome, PFS and
OS were calculated in a secondary landmark analysis, excluding
patients progressing within 6 months while on CT. Restricting the
analysis to 119 patients (39 treated with CT alone and 80 treated
with CT/ET) PFS was signiﬁcantly improved by ET maintenance
(median 17.0 vs. 12.2 months, P ¼ 0.0075), on the contrary OS was
not statistically different (median 47.7 vs. 47.2 months, P ¼ 0.57).
Comparisons of PFS and OS between different treatment groups (CTvs. CT/ET) are presented in Fig. S1 (Supplementary data).
4. Discussion
Our study showed that a CT-based regimen was the preferred
ﬁrst-line therapy in more than one-thirds of the patients with
luminal-like HER2-negative MBC treated in routine clinical prac-
tice. Interestingly, only two factors (i.e. age and bone only meta-
static involvement) had an impact on the therapeutic decision
making process.
After matching for covariates that signiﬁcantly differed between
the two study cohorts of patients (those receiving CT vs. ET as ﬁrst-
line), receiving CT did not signiﬁcantly improve survival compared
to ET.
Current guidelines suggest that ET should be the preferred ﬁrst-
line treatment for luminal-like MBC. However, higher response
rates and faster response associated with CT may induce clinicians
to prescribe ﬁrst-line CT to patients with rapidly progressive,
symptomatic disease or visceral metastases at risk for end-organ
dysfunction.
Few studies explored clinician behavior approaching ﬁrst-line of
treatment in MBC patients and their data are consistent with our
ﬁndings [13e15].
Patients with HER2-positive, hormone receptor-positive MBC
were excluded by analysis. Chemotherapy, combined with HER2-
targeted therapy is the preferred ﬁrst-line approach. Actually, few
studies compared ET with or without anti-HER2 drugs with no
studies directly comparing ET versus CT both combined with HER2-
targeted therapy [16,17]. Patients with HER2-positive luminal-like
MBC were included in ﬁrst-line CT plus anti-HER2 trials. In CLEO-
PATRA trial, for example, about 48% (388/808) of patients had
luminal-like disease and exploratory analyses in predeﬁned sub-
groups showed a consistent beneﬁt with pertuzumab also in ER-
positive population (HR 0.71, 95% C.I. 0.53e0.96) [18]. Initial ther-
apy with endocrine agents is usually restricted to women who are
not eligible for CT or for whom CT is not deemed to be immediately
necessary for disease control.
Intriguingly, our data showed that Ki-67 status, previous treat-
ment for early disease and presence of lung, liver or CNSmetastases
were not associated with treatment choice. Presence of bone me-
tastases was the only disease characteristic associated with choice
of ﬁrst-line treatment. Results about molecular subtypes could be
partly affected by changes in evidence over time.
In daily clinical practice, switching to maintenance ET during
ﬁrst-line CT (usually at least after 6 months of CT) is a commonly
employed strategy aiming to reduce treatment side effects without
compromising OS [19e21]. In our series, the lack of previous neo-
adjuvant or adjuvant ET was associated with higher use of main-
tenance ET.
Nonetheless, due to the small sample size, a note of caution is
needed in interpreting these ﬁndings.
With the limitations of a non-randomized comparison, no sig-
niﬁcant differences were seen in terms of outcome depending on
the ﬁrst-line choice. Recommendation of initiating ET was essen-
tially based on results from a systematic review and its updates
[22], published in the Cochrane Database of Systematic Reviews,
which compared starting treatment with CT versus ET. Pooled
analysis of data from 8 trials showed a signiﬁcant advantage in
terms of response rate for CT over ET. Of note, no signiﬁcant dif-
ference was observed in terms of OS (HR 0.94, with a test for het-
erogeneity giving a P value of 0.1) and, on subset analysis, there was
no obvious trend to suggest an effect of age, menopausal status or
pattern of metastatic disease on the efﬁcacy of either therapy. Only
10 studies were available to provide information on response to
treatment and outcome. Notably, a major limitation to these
Fig. 2. Outcome according to ﬁrst-line treatment choice. Kaplan-Meier estimator plot comparing prognosis of chemo versus endocrine treated patients in terms of overall survival
and progression free survival, both in the complete dataset (panel A) and after propensity score matching (panel B). (CT, chemotherapy; ET, endocrine therapy; OS, Overall Survival;
PFS, Progression Free Survival).
Table 3
Survival prior to matching: prognosis factors in univariate and multivariate (BMI, Body Mass Index; CNS, Central Nervous System; CI, Conﬁdence Interval; CT, Chemotherapy;
ECOG, Eastern Cooperative Oncology Group; ET, Endocrine Therapy; HR, Hazard Ratio; MBC, Metastatic Breast Cancer). Bold values indicate statistically signiﬁcant results.
Chemotherapy Endocrine therapy
Univariate Multivariate Univariate Multivariate
HR [CI 95%] P value HR [CI 95%] P value HR [CI 95%] P value HR [CI 95%] P value
Overall survival Subtype-Luminal B 1.14 [0.69e1.88] 0.61 1.93 [1.33e2.81] 0.001 1.86 [1.27e2.72] 0.001
BMI >25 1.39 [0.88e2.20] 0.16 0.99 [0.69e1.42] 0.95
ECOG performance status >1 1.22 [0.63e2.36] 0.55 1.93 [1.31e1.42] 0.001 1.96 [1.31e2.95] 0.001
Age 70 1.67 [0.98e2.86] 0.06 2.04 [1.50e2.78] <0.0001 1.83 [1.31e2.58] <0.0001
CT naïve 0.61 [0.41e0.92] 0.02 0.85 [0.44e1.62] 0.61 0.96 [0.71e1.30] 0.78
ET naïve 0.63 [0.42e0.95] 0.03 0.67 [0.33e1.36] 0.27 0.76 [0.56e1.04] 0.08
De novo advanced disease 0.60 [0.39e0.93] 0.02 0.95 [0.44e2.04] 0.89 0.89 [0.67e1.17] 0.39
Bone only 0.97 [0.62e1.53] 0.90 0.82 [0.61e1.12] 0.21
Liver metastases 1.39 [0.92e2.09] 0.12 2.97 [1.98e4.45] <0.0001 1.77 [1.06e2.96] 0.03
Lung metastases 1.41 [0.90e2.18] 0.13 1.56 [0.95e2.56] 0.08
CNS metastases 1.63 [0.40e6.62] 0.50 39.69 [11.26e139.9] <0.0001 NA NA
Visceral metastases 1.33 [0.90e1.98] 0.15 2.11 [1.52e2.91] <0.0001 NA NA
Number of sites >1 1.85 [1.26e2.73] 0.002 1.91 [1.29e2.84] 0.001 2.80 [1.96e3.98] <0.0001 1.91 [1.23e2.97] 0.004
Number of lines for MBC 0.86 [0.79e0.93] <0.0001 0.84 [0.77e0.92] <0.0001 0.93 [0.87e0.99] 0.03 0.97 [0.89e1.05] 0.48
Progression free survival Subtype-Luminal B 1.15 [0.75e1.77] 0.51 1.77 [1.30e2.43] <0.0001 1.82 [1.32e2.50] <0.0001
BMI >25 1.25 [0.86e1.81] 0.25 0.94 [0.69e1.30] 0.72
ECOG Performance status >1 0.88 [0.53e1.46] 0.63 1.31 [0.94e1.83] 0.11
Age 70 1.49 [0.94e2.38] 0.09 1.24 [0.95e1.62] 0.11
CT naive 0.66 [0.48e0.92] 0.01 0.89 [0.53e1.51] 0.67 0.77 [0.59e1.00] 0.05
ET naive 0.61 [0.44e0.85] 0.004 0.55 [0.29e1.04] 0.07 0.75 [0.58e0.98] 0.04 0.65 [0.49e0.86] 0.003
De novo advanced disease 0.67 [0.47e0.95] 0.03 1.21 [0.61e2.42] 0.58 0.89 [0.67e1.17] 0.39
Bone only 0.94 [0.63e1.39] 0.75 0.87 [0.67e1.13] 0.31
Liver metastases 1.40 [0.99e1.99] 0.06 2.19 [1.51e3.17] <0.0001 1.48 [0.94e2.31] 0.08
Lung metastases 1.27 [0.87e1.84] 0.21 1.02 [0.68e1.53] 0.91
CNS metastases 0.56 [0.14e2.27] 0.42 7.44 [2.35e23.60] 0.001 NA NA
Visceral metastases 1.24 [0.89e1.72] 0.20 1.53 [1.15e2.03] 0.003 NA NA
Number of sites >1 1.44 [1.03e2.01] 0.03 1.52 [1.08e2.12] 0.02 1.82 [1.31e2.53] <0.0001 1.44 [0.96e2.18] 0.08
M. Bonotto et al. / The Breast 31 (2017) 114e120118
M. Bonotto et al. / The Breast 31 (2017) 114e120 119ﬁndings is thatmost patients in these trials had tumors of unknown
hormone receptor status, since the predictive value of this char-
acteristic on response to ET was not yet appreciated.
Data from our unselected real world population conﬁrmed no
signiﬁcant difference in terms of survival (i.e. both PFS and OS) for
CT versus ET. This result derived from analysis by a propensity score
matching, applied to minimize confounding and indication bias.
Even though propensity score matching simulates randomization,
it is capable to correct only known confounders. Because of this, it
cannot be considered a reliable substitute for randomization. Data
on response were not evaluated due to the retrospective design of
the study.
It is therefore difﬁcult to identify potential predictive factors of
beneﬁt from ET or CT. Of interest, hazard ratio analysis showed that
status of Ki-67 (luminal B vs. luminal A) was relevant only for ET
suggesting a different impact of this variable between two different
cohorts of treatment. Another noteworthy issue is the impact of
previous (neo-adjuvant) therapies in the treatment choice and in
terms of outcome. If on one hand, being ET and CT naïve as well as
the time to relapse did not inﬂuence ﬁrst-line treatment choice, on
the other hand being ET naïve was associated with better PFS in ET
treatment cohorts. Patients ET naïve were, for the most part, those
with de novo advanced disease. Disease burdenwas associated with
worse survival in both cohorts.
Among patients treated with ﬁrst-line CT, better outcome was
observed in those that received ET maintenance and it might be
hypothesized that this part of the treatment could have improved
prognosis of ﬁrst-line CT group. In fact, restricting the analysis to
patients who not underwent disease progression within 6 months
after starting CT, PFS was improved by ET maintenance.
5. Conclusion
This study is based on an analysis of a large series of BC patients
treated in two high-volume academic centers. Data describe a
“real-life” scenario taking in consideration clinical records starting
from 2004 and therefore focusing on modern regimens, differently
from previous similar studies that were limited to cohorts treated
between 1990 and early 2000s. On the other hand, the present
study did not analyze objective response (which could be ques-
tionable when considered retrospectively) and no quality of life
data were available. Propensity score analysis attempted to reduce
but not neutralized limitations of a non-randomized study.
Nonetheless, retrospective observational trial offers an inter-
esting insight on treatment strategy for luminal-like MBC. Differ-
ences between endocrine therapy and chemotherapy have never
been observed in prospective dedicated trials and in a meta-
analysis. In addition, no new generation trials directly compared
endocrine therapy versus chemotherapy. Therefore, development
of endocrine treatment ran parallel but distinct to chemotherapy,
making choice of sequence complex in everyday practice.
In addition, as already shown in a recent paper in different
setting of BC patients [23], depth analysis of treatment population
characteristics in a real-life series provides useful information to
interpret guideline adherence, evaluate patterns of care and moti-
vate quality of care improvement.
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